undamentalytics Newsletter

Barrett M James and related entities: insider trades

Director, 10% owner at 6 companies we cover. 5 open-market purchases and 10 sales not made under a pre-set plan, reported from August 16, 2013 to May 11, 2018. Trades reported separately by several related funds or companies are counted once, under this name.

Would copying Barrett M James and related entities’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 3 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on June 10, 2015 into $4,774 by November 2, 2026, −6.3% a year. The copy held shares only 19% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $15,719, +4.1% a year (the S&P 500 held throughout made $43,329, +13.8% a year). Beta against the index was 0.20. Twelve months after each report, the average purchase was −33.6% against the S&P 500 (median −45.1%), and 33% beat it. Measured from the trade date, the insider’s own timing, the average was −26.7%. After their sales, the shares moved −1.9% against the index over 12 months on average (a negative figure means selling was the right call); 40% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $43.3k$15.7k$4.8k
Copying Barrett M James and related entitiesS&P 500, same days investedS&P 500, held throughout $10,000 copying Barrett M James and related entities’s open-market purchases from June 10, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−6.3%
S&P 500, same days invested
+4.1% (held throughout +13.8%)
Time in shares
19%
Sharpe ratio (S&P 500)
−0.11 (0.69)
Biggest drop (S&P 500)
−81% (−34%)
Market sensitivity (beta)
0.20
Purchases copied
3

Trade by trade

Barrett M James and related entities: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 3 +10.8% +27.0% 67% 2 — — Not enough years
Purchases, 6 months after the report 3 +7.7% +21.0% 67% 2 — — Not enough years
Purchases, 12 months after the report 3 −33.6% −45.1% 33% 2 — — Not enough years
Purchases, 12 months after the trade 3 −26.7% −37.0% 33% 2 — — Not enough years
Sales, 3 months after the report 10 −4.2% −10.3% 60% 4 −1.75 0.18 No reliable evidence
Sales, 12 months after the report 10 −1.9% +6.8% 40% 4 −1.00 0.39 No reliable evidence
Sales, 12 months after the trade 10 −1.4% +11.8% 40% 4 −1.12 0.34 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Supernus Pharmaceuticals, Inc. SUPN —06June 17, 2015December 8, 2015
Ardelyx, Inc. ARDX —31December 29, 2014July 20, 2016
Senseonics Holdings, Inc. SENS —20March 23, 2016June 5, 2017
Groupon, Inc. GRPN —01August 16, 2013August 16, 2013
Gyre Therapeutics, Inc. GYRE —01December 5, 2013December 5, 2013
Crescent Biopharma, Inc. CBIO —01May 11, 2018May 11, 2018

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 11, 2018May 10, 2018 CBIO Sale $169,890 −27.6%−41.1%−39.8%
June 5, 2017June 1, 2017 SENS Purchase $9,999,999 not yetnot yetnot yet
July 20, 2016July 18, 2016 ARDX Purchase $6,666,664 +27.0%−63.4%−61.7%
March 23, 2016March 23, 2016 SENS Purchase $4,499,999 not yetnot yetnot yet
January 14, 2016January 13, 2016 ARDX Purchase $5,000,000 −34.0%+7.8%+18.6%
December 8, 2015December 4, 2015 SUPN Sale $3,100,105 +7.9%+40.8%+44.6%
November 30, 2015November 25, 2015 SUPN Sale $264,527 −11.7%+22.1%+30.6%
November 18, 2015November 17, 2015 SUPN Sale $1,545,000 −9.2%+32.3%+33.3%
November 17, 2015November 13, 2015 SUPN Sale $1,942,954 −11.4%+42.4%+38.3%
June 19, 2015June 17, 2015 SUPN Sale $1,833,339 +22.9%+8.9%+14.6%
June 17, 2015June 16, 2015 SUPN Sale $928,519 +29.4%+4.6%+9.0%
June 9, 2015June 5, 2015 ARDX Purchase $20,000,001 +39.4%−45.1%−36.9%
December 29, 2014December 26, 2014 ARDX Sale $54,716 −30.0%−0.3%−12.9%
December 5, 2013December 3, 2013 GYRE Sale $85,830 −14.8%−71.9%−73.3%
August 16, 2013August 15, 2013 GRPN Sale $307,179 +2.9%−57.2%−58.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Barrett M James and related entities traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.